Breakthrough Therapy for Advanced Heart Failure: BIOVAT-HF Trial Outcomes Published in NEJM

(SeaPRwire) –   Repairon Announces Publication of BioVAT-HF Clinical Trial Results for Engineered Human Heart Muscle Tissue in the New England Journal of Medicine

GÖTTINGEN, Germany and PROVIDENCE, R.I., May 28, 2026 — Repairon, a biotechnology firm focused on regenerative cardiac treatments, today reported that clinical trial data evaluating its engineered human heart muscle tissue for patients suffering from advanced heart failure have been published in the New England Journal of Medicine (NEJM). The study concludes that it is possible to restore heart muscle function in advanced heart failure patients, leading to enhanced health and quality of life. Publication details: Zimmermann WH, Ensminger S, Kutschka I, et al. Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure. N Engl J Med. May 28;394(20):1991-2001 DOI: 10.1056/NEJMoa2513525

The findings stem from the BioVAT-HF (BiologicalVentricularAssistTissue in TerminalHeartFailure) clinical trial. This Phase 1-2 study, designed to evaluate safety and preliminary efficacy, involved the implantation of fully functional heart muscle patches—engineered from human induced pluripotent stem cell-derived, terminally differentiated heart muscle cells—onto the compromised left ventricular muscle of patients with advanced heart failure with reduced ejection fraction (HFrEF), in addition to standard medical therapy. The trial commenced with a dose-escalation phase to determine the maximum safe dose, followed by treatment at that level to further assess safety and efficacy. Out of 20 enrolled patients, 16 received the maximum safe dose. At the time of the report, the most recently enrolled patient had completed 3 months of follow-up, with total follow-up periods for the cohort ranging from 6 to 52 months.

Regarding safety, the NEJM publication notes that 3 patient deaths occurred during the study; the Data Safety Monitoring Board determined these were unrelated to the BioVAT. Most severe adverse events were linked to underlying cardiac conditions, concurrent illnesses, or immunosuppression that necessitated adjustments to the treatment regimen. Three patients experienced ventricular tachycardia, which was deemed unrelated to the BioVAT transplant. No instances of ventricular fibrillation were reported. Among the 16 patients who received the maximum safe dose, 2 experienced hospitalizations due to heart failure.

Efficacy results from the NEJM publication for patients receiving the maximum safe dose showed the following improvements from baseline:

• Target heart wall thickness increased by 4.5 mm at 3 months and 2.9 mm at 12 months of follow-up.
• Left ventricular ejection fraction improved by 3.9% at 3 months and 6.9% at the final follow-up point.
• Quality of Life, as assessed by the KCCQ-OSS, rose by 6.7 points at 3 months and 15 points at 12 months of follow-up.

The study results corroborate preclinical data suggesting that engineered heart muscle can integrate with damaged myocardium, create a vascularized layer, and contract in rhythm with native tissue. This was further validated by the analysis of an explanted heart from a patient in the dose-finding cohort who subsequently underwent a cardiac transplant, providing clear evidence of human heart remuscularization and corresponding gains in wall thickness, ejection fraction, and quality of life. The authors suggest that further clinical research with extended follow-up periods is necessary.

Wolfram-Hubertus Zimmermann, MD, professor and director of the Institute of Pharmacology and Toxicology at the University Medical Center Goettingen, Germany, and lead author of the NEJM publication, noted: “Current heart failure treatments often only slow disease progression; they cannot replace destroyed heart muscle. Our objective is to create new, functional heart muscle tissue to provide targeted support to the failing heart.”

Lothar Germeroth, Ph.D., CEO of Repairon, stated: “We are highly encouraged by these Phase II results, which we believe confirm the therapeutic potential of our regenerative cardiac patch platform. Heart failure remains a leading cause of global morbidity and mortality, and we believe these findings may initiate a new era in myocardial regeneration and restorative cardiovascular medicine.”

Significant medical need in advanced heart failure: Approximately 5% of the global population is affected by chronic heart failure of varying severity, making it a primary cause of death. In the United States, heart failure is the leading cause of hospitalization and mortality among the elderly, impacting over 6 million individuals. As the condition reaches advanced stages, patients suffer from weakness and discomfort during all physical activities and even at rest, sometimes requiring constant bed rest. For these severely ill patients, the only available treatment options are currently mechanical pump devices or heart transplantation.

About Repairon: Repairon GmbH is a biotechnology company based in Göttingen, Germany, specializing in the development of regenerative cell therapies for cardiac medicine. Founded in 2014, the company is based on research by MD Wolfram-Hubertus Zimmermann and his team at the University Medical Center Goettingen, who have pioneered several tissue engineering technologies applicable to organ repair and drug development. Repairon’s lead candidate, the human engineered heart muscle patch, is currently being studied in the BioVAT-HF Phase 2 clinical trial as a biological ventricular assist tissue (BioVAT) for end-stage heart failure.